HuR Multimerization Inhibitors for Cancer and Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies targeting HuR multimerization in cancer and inflammation lack effective small molecule inhibitors, which are crucial for addressing pathological processes driven by HuR multimer formation in various disease states.
Innovation Solution
Development of a class of compounds that inhibit HuR multimerization with high affinity, providing therapeutic options for diseases related to neoplastic progression and inflammation by preventing HuR multimer formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibitors are developed to target HuR multimerization, then therapeutic effectiveness against cancer and inflammation is improved, but the complexity of drug development and characterization increases
Solution Approach 1:
The patent uses a peptide-based inhibitor as an intermediary molecule to block HuR multimerization. The peptide acts as a mediator that specifically binds to HuR's dimerization interface, preventing pathological multimer formation without requiring complex small molecule structures. This approach simplifies the drug development process while maintaining therapeutic effectiveness.
Solution Approach 2:
The invention modifies the chemical parameters of the inhibitor by using a peptide backbone with specific amino acid sequences rather than traditional small molecule structures. This parameter change allows the inhibitor to achieve high affinity for HuR multimers through specific sequence-based recognition, simplifying the development process while improving therapeutic reliability.
2Object-affected harmful factors
If compounds are designed to inhibit HuR multimerization with high affinity, then pathological processes are more effectively suppressed, but the specificity and selectivity requirements for the compounds increase
Solution Approach 1:
The patent applies local quality by designing the peptide inhibitor to specifically target the dimerization interface of HuR with precise amino acid sequence requirements. The inhibitor's N-terminal and C-terminal regions are optimized to bind specific residues at the HuR-HuR interaction interface, ensuring high specificity while effectively suppressing pathological multimerization processes.
Solution Approach 2:
The peptide inhibitor is segmented into specific functional regions with defined amino acid sequences that independently contribute to binding affinity and specificity. This segmentation allows for modular optimization of the inhibitor's interaction with HuR, enabling precise control over specificity requirements while achieving effective suppression of pathological processes.
3Productivity
If HuR multimerization is inhibited to treat cancer and inflammation, then disease progression is slowed, but the understanding and characterization of HuR's role in various diseases must be deepened
Solution Approach 1:
The patent performs preliminary characterization of HuR's role in cancer and inflammation before developing the therapeutic inhibitor. Extensive preclinical studies establish the pathological significance of HuR multimerization in these diseases, creating a knowledge base that guides inhibitor development and ensures that slowing disease progression is achieved through understanding of specific disease mechanisms.
Solution Approach 2:
The invention incorporates feedback mechanisms where the effects of HuR multimerization inhibition are continuously monitored and used to refine understanding of disease mechanisms. Preclinical and clinical data on the inhibitor's effects feed back into the characterization of HuR's role in disease, deepening understanding while simultaneously achieving disease progression control.
Data Source
AI summary
This disclosure provides compounds that inhibit RNA-binding proteins, such as Human antigen R protein (HuR). The compounds described herein have a high affinity for HuR multimers and inhibit the pathological processes that promote cancer and inflammation. The compounds are highly water-soluble and have good biodistribution for both systemic and central nervous system disease processes. The compounds provide a unique therapeutic option for disease processes related to neoplastic progression or acute or chronic inflammation.